Open AccessAntiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study
Author(s) -
Fanaroff Alexander C.,
Kaltenbach Lisa A.,
Peterson Eric D.,
Akhter Mohammed W.,
Effron Mark B.,
Henry Timothy D.,
Wang Tracy Y.
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007982
Subject(s) - medicine , prasugrel , ticagrelor , clopidogrel , acute coronary syndrome , cardiology , percutaneous coronary intervention , myocardial infarction , aspirin
Guidelines recommend P2Y 12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is provided on antiplatelet management for patients with recurrent ischemic events during that year. We describe changes in P2Y 12 inhibitor type among patients with recurrent ischemic events in the first year after MI.